Table 3.
Association between long-term exposure to statins (at least 5 years) and the risk of MPN based on the subgroups
| Subgroup | Cases exposed/unexposed, n/n | Controls exposed/unexposed, n/n | OR∗ (95% CI) | aOR† (95% CI) |
|---|---|---|---|---|
| Age group, y | ||||
| <60 | 46/825 | 189/4386 | 1.33 (0.94-1.88) | 0.80 (0.52-1.25) |
| 60-75 | 330/1089 | 1772/5546 | 0.94 (0.82-1.08) | 0.77 (0.65-0.91) |
| >75 | 282/570 | 1662/2759 | 0.79 (0.67-0.93) | 0.65 (0.54-0.78) |
| Sex | ||||
| Male | 300/1228 | 1882/6146 | 0.76 (0.66-0.88) | 0.57 (0.47-0.68) |
| Female | 358/1256 | 1741/6545 | 1.06 (0.92-1.22) | 0.88 (0.75-1.04) |
| Disease subtype | ||||
| PV | 236/829 | 1270/4350 | 0.93 (0.79-1.11) | 0.73 (0.59-0.89) |
| ET | 215/876 | 1 130/4520 | 0.98 (0.82-1.17) | 0.89 (0.72-1.10) |
| MF | 102/366 | 600/1790 | 0.83 (0.64-1.07) | 0.60 (0.44-0.82) |
| MPN-U | 105/413 | 623/2031 | 0.78 (0.60-0.99) | 0.52 (0.39-0.71) |
| No diabetes | 494/2404 | 2544/12 291 | 0.95 (0.84-1.06) | 0.70 (0.63-0.82) |
| No AD | 581/2297 | 3250/11 741 | 0.88 (0.79-0.98) | 0.69 (0.60-0.78) |
∗
Adjusted for age, sex, and calendar time (by matching design).
†
Adjusted for (∗) in addition to (1) education level (primary school, high school, short/intermediate education, or long education); (2) Charlson Comorbidity Index (0, 1, or ≥2); (3) previous use of aspirin, other nonsteroidal anti-inflammatory drugs, alendronate, immunosuppressants, and metformin; and (4) previous history of alcohol-related diagnoses, overweight- and obesity-related diagnoses, chronic obstructive pulmonary disease, AD, and diabetes.